Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Max IndiaNSE:MAXIND +8.92%64 3-1 Month Momentum % is -10.40% as of Sep. 21, 2026. GuruFocus rates NSE:MAXIND with a GF Score™ of 64/100 and a GF Value™ of ₹230.61 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 670 Healthcare Providers & Services companies, Max India ranks worse than 80.9% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-21), Max India's 3-1 Month Momentum % is -10.40%.
The industry rank for Max India's 3-1 Month Momentum % or its related term are showing as below:
NSE:MAXIND's 3-1 Month Momentum % is ranked worse than 80.9% of 670
companies
in the Healthcare Providers & Services industry
Industry Median: 0.56
vs NSE:MAXIND: -10.40
Max India (NSE:MAXIND) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Max India 3-1 Month Momentum % Related Terms
NSE:MAXIND vs HCA, THC, EHC: 3-1 Month Momentum % Comparison
For the Medical Care Facilities subindustry, Max India's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Max India 3-1 Month Momentum % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Max India's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Max India's 3-1 Month Momentum % falls into.
Max India (NSE:MAXIND) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Max India (NSE:MAXIND) has a 3-1 Month Momentum % of -10.40% as of Sep. 21, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Max India and its competitors. According to the industry distribution chart, Max India ranks #542 out of 670 companies in the Healthcare Providers & Services industry, placing it in the top 80.9%.
Is Max India's 3-1 Month Momentum % too high?
Max India's current 3-1 Month Momentum % is -10.40%. Based on the distribution chart, Max India ranks #542 out of 670 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Max India has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Max India's 3-1 Month Momentum % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Max India ranks #542 out of 670 companies for 3-1 Month Momentum %. This places Max India in the lower half of its industry. The industry median 3-1 Month Momentum % is 0.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Healthcare Providers & Services company?
The median 3-1 Month Momentum % among Healthcare Providers & Services companies is 0.56, based on 670 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Max India and its competitors. For the Healthcare Providers & Services industry, the median 3-1 Month Momentum % is 0.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Max India's current 3-1 Month Momentum % is -10.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Max India stock overvalued right now?
Based on GuruFocus' analysis, Max India (NSE:MAXIND) is currently considered Possible Value Trap. The stock's GF Value™ is ₹230.61, compared to a current price of ₹152.69 — trading 33.8% below its estimated fair value. The current 3-1 Month Momentum % is -10.40%. Max India's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Max India (NSE:MAXIND), the current 3-1 Month Momentum % is -10.40% as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Max India (NSE:MAXIND) Overvalued in 2026?
Based on GuruFocus' analysis, Max India stock appears to be undervalued.
The current stock price of ₹152.69 is trading 33.8% below its estimated GF Value™ of ₹230.61.
GuruFocus considers Max India to be Possible Value Trap.
Key valuation signals for NSE:MAXIND:
3-1 Month Momentum %: -10.40%
GF Value™: ₹230.61 vs. price of ₹152.69 (33.8% below fair value)
No single metric tells the full story. See the NSE:MAXIND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Max India Ltd is a multi-business corporate that operates in the healthcare sector. The company provides healthcare services. Also, the company provides health insurance policies, senior-living communities, and other health-related training services. The business operates in four segments namely, Business Investments, Senior Living, Assisted Care, and Other. It derives maximum revenue from Senior Living segment.
64GF Score
Get the complete analysis for NSE:MAXIND
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MAXIND has been successfully added to your 
